Randolph Co Inc Takes $301,000 Position in Edwards Lifesciences Corporation $EW

Key Points

• Randolph Co Inc acquired 3,852 shares of Edwards Lifesciences Corporation valued at approximately $301,000 during the 2nd quarter, highlighting growing interest from institutional investors.
• Analysts have raised their price targets for Edwards Lifesciences, with Mizuho increasing their target from $87.00 to $95.00 and at least three analysts rating the stock with a Strong Buy.
• The company reported a quarterly earnings of $0.67 per share, exceeding expectations, and experienced a 11.9% year-over-year revenue growth to $1.53 billion.

Randolph Co Inc purchased a new position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 3,852 shares of the medical research company's stock, valued at approximately $301,000.

A number of other institutional investors have also recently added to or reduced their stakes in EW. CX Institutional boosted its position in Edwards Lifesciences by 10.7% in the 2nd quarter. CX Institutional now owns 4,314 shares of the medical research company's stock valued at $337,000 after buying an additional 416 shares during the last quarter. Bank Pictet & Cie Europe AG boosted its holdings in Edwards Lifesciences by 254.2% in the second quarter. Bank Pictet & Cie Europe AG now owns 20,906 shares of the medical research company's stock valued at $1,635,000 after purchasing an additional 15,004 shares during the last quarter. Dakota Wealth Management grew its stake in Edwards Lifesciences by 2.5% during the 2nd quarter. Dakota Wealth Management now owns 6,048 shares of the medical research company's stock valued at $473,000 after purchasing an additional 146 shares in the last quarter. Perigon Wealth Management LLC increased its holdings in Edwards Lifesciences by 11.0% during the 2nd quarter. Perigon Wealth Management LLC now owns 4,799 shares of the medical research company's stock worth $375,000 after purchasing an additional 474 shares during the last quarter. Finally, TD Private Client Wealth LLC purchased a new stake in Edwards Lifesciences during the 2nd quarter worth approximately $169,000. Institutional investors and hedge funds own 79.46% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Mizuho increased their target price on Edwards Lifesciences from $87.00 to $95.00 and gave the company an "outperform" rating in a research note on Friday, July 25th. Evercore ISI increased their price objective on shares of Edwards Lifesciences from $77.00 to $80.00 and gave the company an "in-line" rating in a research note on Friday, July 25th. Robert W. Baird raised their price objective on shares of Edwards Lifesciences from $78.00 to $79.00 and gave the stock a "neutral" rating in a report on Friday, July 25th. Morgan Stanley upped their target price on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the company an "equal weight" rating in a research note on Tuesday, July 15th. Finally, Dbs Bank raised shares of Edwards Lifesciences to a "hold" rating in a research report on Monday, June 2nd. Three analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Edwards Lifesciences has an average rating of "Moderate Buy" and an average target price of $86.61.

Edwards Lifesciences Stock Up 0.9%

EW stock opened at $75.35 on Friday. The firm has a market cap of $44.24 billion, a price-to-earnings ratio of 10.84, a PEG ratio of 3.59 and a beta of 1.07. Edwards Lifesciences Corporation has a 1-year low of $64.00 and a 1-year high of $83.00. The firm has a fifty day moving average price of $78.50 and a two-hundred day moving average price of $75.62. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.49 billion. During the same period last year, the firm posted $0.70 EPS. The company's revenue for the quarter was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Research analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insider Activity at Edwards Lifesciences

In other news, insider Larry L. Wood sold 8,950 shares of the stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the sale, the insider directly owned 206,900 shares in the company, valued at approximately $16,150,614. This represents a 4.15% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Daniel J. Lippis sold 4,114 shares of the firm's stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the completion of the sale, the vice president directly owned 22,002 shares in the company, valued at approximately $1,748,278.92. This trade represents a 15.75% decrease in their position. The disclosure for this sale can be found here. 1.29% of the stock is currently owned by corporate insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.